Selected Publications from PandeyLab

For a full list scroll down

J Clin Invest . 2022 Dec 20;e164915. doi: 10.1172/JCI164915

Loss of LGR4/GPR48 causes severe neonatal salt-wasting due to disrupted WNT signaling altering adrenal zonation.

Int J Mol Sci . 2022 Sep 4;23(17):10141. doi: 10.3390/ijms231710141

Loss of Protein Stability and Function Caused by P228L Variation in NADPH-Cytochrome P450 Reductase Linked to Lower Testosterone Levels

Front Pharmacol . 2022 Oct 5;13:931089. doi: 10.3389/fphar.2022.931089

Variant predictions in congenital adrenal hyperplasia caused by mutations in CYP21A2

Front Endocrinol (Lausanne) . 2022 Sep 29;13:981090. doi: 10.3389/fendo.2022.981090

Recognition of fold- and function-specific sites in the ligand-binding domain of the thyroid hormone receptor-like family

Nat Commun . 2021 Apr 15;12(1):2260. doi: 10.1038/s41467-021-22562-w

Biased cytochrome P450-mediated metabolism via small-molecule ligands binding P450 oxidoreductase

Int J Mol Sci . 2020 Sep 26;21(19):7102. doi: 10.3390/ijms21197102

Finding New Molecular Targets of Familiar Natural Products Using In Silico Target Prediction

Nature Genetics volume 36, pages 228–230 (2004)

Mutant P450 oxidoreductase causes disordered steroidogenesis with and without Antley-Bixler syndrome.

AJHG Volume 76, Issue 5, May 2005, Pages 729-749

Diversity and Function of Mutations in P450 Oxidoreductase in Patients with Antley-Bixler Syndrome and Disordered Steroidogenesis

Pharmacology & Therapeutics Vol 138, (2), May 2013, Pages 229-254

NADPH P450 oxidoreductase: Structure, function, and pathology of diseases.

Regulation of 17,20 Lyase Activity by Cytochrome b5 and by Serine Phosphorylation of P450c17

Inhibition of placental CYP19A1 activity remains as a valid hypothesis for 46,XX virilization in P450 oxidoreductase deficiency

Proc Natl Acad Sci U S A. 2020 Jun 30;117(26):14632-14633. doi: 10.1073/pnas.2003154117

Publications

 

  1. Rojas Velazquez MN, Noebauer M, Pandey AV. Loss of Protein Stability and Function Caused by P228L Variation in NADPH-Cytochrome P450 Reductase Linked to Lower Testosterone Levels. Int J Mol Sci. 2022 Sep 4;23(17):10141. doi: 10.3390/ijms231710141. PMID: 36077536
  2. Lucas C, Sauter KS, Steigert M, Mallet D, Wilmouth J, Olabe J, Plotton, I, Morel Y, Aeberli D, Wagner F, Clevers H, Pandey AV, Val P, Roucher Boulez F, Fluck CE. Loss of LGR$/GPR48 causes severe neonatal salt-wasting due to disrupted WNT signaling altering adrenal zonation. J Clin Investigation 2022 (In Press).
  3. Prado MJ, Ligabue-Braun R, Zaha A, Rossetti MLR, Pandey AV. Variant predictions in congenital adrenal hyperplasia caused by mutations in CYP21A2. Front Pharmacol. 2022 Oct 5;13:931089. doi: 10.3389/fphar.2022.931089. PMID: 36278220
  4. Verma S, Chakraborti S, Singh OP, Pande V, Dixit R, Pandey AV, Pandey KC. Recognition of fold- and function-specific sites in the ligand-binding domain of the thyroid hormone receptor-like family. Front Endocrinol. 2022 Sep 29;13:981090. doi: 10.3389/fendo.2022.981090. PMID: 36246927
  5. Wróbel TM, Rogova O, Sharma K, Rojas Velazquez MN, Pandey AV, Jørgensen FS, Arendrup FS, Andersen KL, Björkling F. Synthesis and Structure-Activity Relationships of Novel Non-Steroidal CYP17A1 Inhibitors as Potential Prostate Cancer Agents. Biomolecules. 2022 Jan 20;12(2):165. doi: 10.3390/biom12020165. PMID: 35204665
  6. Prado MJ, Singh S, Ligabue-Braun R, Meneghetti BV, Rispoli T, Kopacek C, Monteiro K, Zaha A, Rossetti MLR, Pandey AV. Characterization of Mutations Causing CYP21A2 Deficiency in Brazilian and Portuguese Populations. Int J Mol Sci. 2022 Dec 28;23(1):296. doi: 10.3390/ijms23010296. PMID: 35008721
  7. Simon B Jensen, Sara Thodberg, Shaheena Parween, Matias E. Moses, Cecilie T Hansen, Johannes Thomsen, Magnus B. Sletfjerding, Camilla Knudsen, Rita Giudice, Philip Lund, Patricia Castano, Yanet Bustamante, Maria Natalia Velasquez, Flemming S Jørgensen, Amit V. Pandey, Tomas Laursen,  Birger L Møller, Nikos Hatzakis. Biased cytochrome P450-mediated metabolism via small-molecule ligands binding P450 oxidoreductase.  Nature Communications 2021 Apr 15;12(1):2260. doi: 10.1038/s41467-021-22562-w.PMID: 33859207
  8. Humbert M, Seiler K, Mosimann S, Rentsch V, Sharma K, Pandey AV, McKenna SL, Tschan MP. Reducing FASN expression sensitizes acute myeloid leukemia cells to differentiation therapy. Cell Death Differ. 2021 Mar 19. doi: 10.1038/s41418-021-00768-1. PMID: 33742137.
  9. Parween S, Fernández-Cancio M, Benito-Sanz S, Camats N, Rojas Velazquez MN, López-Siguero JP, Udhane SS, Kagawa N, Flück CE, Audí L, Pandey AV. Molecular Basis of CYP19A1 Deficiency in a 46,XX Patient With R550W Mutation in POR:Expanding the PORD Phenotype. J Clin Endocrinol Metab. 2020 Apr 1;105(4). pii:dgaa076. doi: 10.1210/clinem/dgaa076. PMID: 32060549.
  10. Flück CE, Parween S, Rojas Velazquez MN and Pandey AV. Inhibition of placental CYP19A1 activity remains as a valid hypothesis for 46,XX virilization in P450 oxidoreductase deficiencyProc Natl Acad Sci U S A. 2020 Jun 30;117(26):14632-14633. doi: 10.1073/pnas.2003154117
  11. Mayr, F.; Möller, G.; Garscha, U.; Fischer, J.; Rodríguez Castaño, P.; Inderbinen, S.G.; Temml, V.; Waltenberger, B.; Schwaiger, S.; Hartmann, R.W.; Gege, C.; Martens, S.; Odermatt, A.; Pandey, A.V.; Werz, O.; Adamski, J.; Stuppner, H.; Schuster, D. Finding New Molecular Targets of Familiar Natural Products Using In Silico Target Prediction. Int J Mol Sci. 2020 Sep 26;21(19):E7102. doi: 10.3390/ijms21197102.PMID: 32993084
  12. Katharopoulos E, Di Lorgi N, Fernandez-Alvarez P, Pandey AV, Groessl M, Dubey S, Camats N, Napoli F, Patti G, Lezzi M, Maghnie M, Flück CE. Characterization of Two Novel Variants of the Steroidogenic Acute Regulatory Protein Identified in a Girl with Classic Lipoid Congenital Adrenal Hyperplasia. Int J Mol Sci. 2020 Aug 27;21(17):6185. doi: 10.3390/ijms21176185. PMID: 32867102
  13. Stefela A, Kaspar M, Drastik M, Holas O, Hroch A, Smutny T, Skoda J, Hutníková M, Pandey AV,  Kudova E, Pavek P. 3β-Isoobeticholic acid efficiently activates the farnesoid X receptor (FXR) due to its epimerization to 3α-epimer by hepatic metabolism. J Steroid Biochem Mol Biol. 2020 Sep;202:105702. doi: 10.1016/j.jsbmb.2020.105702. PMID: 32505574. 
  14. Parween S, DiNardo G, Baj F, Zhang C, Gilardi G, Pandey AV. Differential effects of variations in human P450 oxidoreductase on the aromatase activity of CYP19A1 polymorphisms R264C and R264H. J Steroid Biochem Mol Biol. 2020 Feb;196:105507. doi: 10.1016/j.jsbmb.2019.105507. Epub 2019 Oct 24. PMID: 31669572.
  15. Praveen, VP; Ladjouze, A; Sauter, Kay-Sara; Pulickal, A; Katharopoulos, E; Trippel, M; Perren, A; Pandey, AV; Flück, CE. Novel CYP19A1 mutations extend the genotype-phenotype correlation and reveal the impact on ovarian function. Journal of the Endocrine Society, 2020 DOI: 10.1210/jendso/bvaa030 https://doi.org/10.1210/jendso/bvaa030
  16. Rodríguez Castaño P, Parween S, Pandey AV. Bioactivity of Curcumin on the Cytochrome P450 Enzymes of the Steroidogenic Pathway. Int J Mol Sci. 2019 Sep 17; 20(18). pii: E4606. doi: 10.3390/ijms20184606. PMID: 31533365.
  17. Malikova J, Zingg T, Fingerhut R, Sluka S, Grössl M, Brixius-Anderko S, Bernhardt R, McDougall J, Pandey AV, Flück CE. HIV Drug Efavirenz Inhibits CYP21A2 Activity with Possible Clinical Implications. Horm Res Paediatr. 2019; 91(4):262-270. doi: 10.1159/000500522. PMID:31256164.
  18. Velazquez MNR, Parween S, Udhane SS, Pandey AV. Variability in human drug metabolizing cytochrome P450 CYP2C9, CYP2C19 and CYP3A5 activities caused by genetic variations in cytochrome P450 oxidoreductase. Biochem Biophys Res Commun. 2019 Jul 12;515(1):133-138. doi: 10.1016/j.bbrc.2019.05.127. Epub 2019 May 23.PubMed PMID: 31128914.
  19. Parween S, Di Nardo, G, Baj F, Chao Z, Gilardi G, Pandey AV. Differential effects of variations in human P450 oxidoreductase on the aromatase activity of CYP19A1 polymorphisms R264C and R264H. The Journal of Steroid Biochemistry and Molecular Biology. Volume 196, 2020, https://doi.org/10.1016/j.jsbmb.2019.105507.
  20. Parween S, Velazquez MNR, Udhane SS, Kagawa N, Pandey AV. Variability in loss of multiple enzyme activities due to the human genetic variation P284T located in the flexible hinge region of NADPH cytochrome P450 oxidoreductase. Front. Pharmacol. doi: 10.3389/fphar.2019.01187 (2019) 
  21. Malikova J, Zingg T, Fingerhut R, Sluka S, Grössl M, Brixius-Anderko S, Bernhardt R, McDougall J, Pandey AV, Flück CE. HIV Drug Efavirenz Inhibits CYP21A2 Activity with Possible Clinical Implications. Horm Res Paediatr. 2019; 91(4):262-270. doi: 10.1159/000500522.PubMed PMID:31256164.
  22. Fernández-Cancio M, Camats N, Flück CE, Zalewski A, Dick B, Frey BM, Monné R, Torán N, Audí L, Pandey AV. Mechanism of the Dual Activities of Human CYP17A1 and Binding to Anti-Prostate Cancer Drug Abiraterone Revealed by a Novel V366M Mutation Causing 17,20 Lyase Deficiency. Pharmaceuticals (Basel). 2018 Apr 29;11(2). pii: E37. doi: 10.3390/ph11020037. PubMed PMID: 29710837
  23. Martinez de la Piscina I, de Mingo C, Riedl S, Rodriguez A, Pandey AV, Fernandez-Cancio M, Camats N, Sinclair A, Castano L, Audi L, Flück CE. GATA4 variants in individuals with a 46,XY disorder of sex development (DSD) may or may not be associated with cardiac defects depending on second hits in other genes. Front. Endocrinol. Doi: 10.3389/fendo.2018.00142 (2018)
  24. Pandey AV, Henderson CJ, Ishi Y, Kranendonk M, Backes WL, Zanger UM. Role of protein protein interaction in metabolism: Genetics, structure, function. Front. Pharmacol. 8: 881. doi: 10.3389/fphar.2017.00881 (2017)
  25.  
  26. Malikova J, Brixius-Anderko S, Udhane SS, Parween S, Dick B, Bernhardt R, Pandey AV. CYP17A1 inhibitor abiraterone, an anti-prostate cancer drug, also inhibits the 21-hydroxylase activity of CYP21A2. J Steroid Biochem Mol Biol. 174: 192-200. doi: 10.1016/j.jsbmb.2017.09.007 (2017).
  27. Udhane SS, Parween S, Kagawa N and Pandey AV. Altered CYP19A1 and CYP3A4 activities due to mutations A115V, T142A, Q153R and P284L in the human P450 oxidoreductase. Front. Pharmacol. 8:580.   doi: 10.3389/fphar.2017.00580 (2017)
  28. Burkhard FZ, Parween S, Udhane SS, Flück CE, Pandey AV. P450 Oxidoreductase deficiency: Analysis of mutations and polymorphisms. J Steroid Biochem Mol Biol. 165: 38-50 (2017) 
  29. Flück CE, Pandey AV. Impact on CYP19A1 activity by mutations in NADPH cytochrome P450 oxidoreductase.  J Steroid Biochem Mol Biol. 165: 64-70 (2017) 
  30. Marti N, Galván JA, Pandey AV, Trippel M, Tapia C, Müller M, Perren A, Flück CE. Genes and proteins of the alternative steroid backdoor pathway for dihydrotestosterone synthesis are expressed in the human ovary and seem enhanced in the polycystic ovary syndrome. Mol Cell Endocrinol. 441: 116-123. (2017) 
  31. Parween S, Boulez FR, Flück CE, Lienhardt-Roussie A, Mallet D, Morel Y, Pandey AV. P450 Oxidoreductase Deficiency: loss of activity caused by protein instability from a novel L374H mutation. J Clin Endocrinol Metab. 101: 4789-4798 (2016) 
  32. Zalewski A, Ma NS, Legeza B, Renthal N, Flück CE, Pandey AV. Vitamin D-Dependent Rickets Type 1 Caused by Mutations in CYP27B1 Affecting Protein Interactions with Adrenodoxin. J Clin Endocrinol Metab. 101:3409-3418. doi: 10.1210/jc.2016-2124. (2016) 
  33. Udhane SS, Dick B, Hu Q, Hartmann RW, Pandey AV. Specificity of anti-prostate cancer CYP17A1 inhibitors on androgen biosynthesis. Biochem Biophys Res Commun. 477:1005-10. doi: 10.1016/j.bbrc.2016.07.019. (2016) 
  34. Inauen C, Rüfenacht V, Pandey AV, Hu L, Blom H, Nuoffer JM, Häberle J. Effect of Cysteamine on Mutant ASL Proteins with Cysteine for Arginine Substitutions. Mol Diagn Ther. 20:125-33. doi: 10.1007/s40291-015-0182-z. (2016) 
  35. Prasad M; Walker AN; Kaur J; Thomas JL; Powell SA; Pandey AV; Whittal RM; Burak WE; Petruzzelli G; Bose HS. Endoplasmic reticulum stress enhances mitochondrial metabolic activity in mammalian adrenals and gonads. Mol. Cell. Biology 36: 3058-3074 (2016) 
  36. Miletta MC, Eblé A, Janner M, Parween S, Pandey AV, Flück CE, Mullis PE. IGHD II: A Novel GH-1 Gene Mutation (GH-L76P) Severely Affects GH Folding, Stability, and Secretion. J Clin Endocrinol Metab. 2015 100 :E1575-83. doi:10.1210/jc.2015-3265. (2015) 
  37. Zhuang L, Pandey AV, Villiger PM, Trueb B. Cell-cell fusion induced by the Ig3 domain of receptor FGFRL1 in CHO cells. Biochim Biophys Acta. (Mol. Cell Res) 1853:2273-2285 (2015). 
  38. Udhane, S, Pandey, AV., Hofer G, Mullis PE and Flück CE. Retinoic acid receptor beta and angiopoietin-like protein 1 are involved in the regulation of human androgen biosynthesis. Scientific Reports 5:10132. doi: 10.1038/srep10132 (2015).
  39. Hu L, Pandey AV, Balmer C, Eggimann S, Rüfenacht V, Nuoffer JM, Häberle J. Unstable argininosuccinate lyase in variant forms of the urea cycle disorder argininosuccinic aciduria. J Inherit Metab Dis. 38: 815-827 (2015).
  40. Pandey, AV and Sproll, P. Pharmacogenomics of human P450 oxidoreductase. Front. Pharmacol. 5:103. doi: 10.3389/fphar.2014.00103 (2014). 
  41. Bouchoucha N, Samara-Boustani D, Pandey AV, Bony-Trifunovic H, Hofer G,Aigrain Y, Polak M, Flück CE. Characterization of a novel CYP19A1 (aromatase) R192H mutation causing virilization of a 46,XX newborn, undervirilization of the 46,XY brother, but no virilization of the mother during pregnancies. Mol Cell Endocrinol. 390: 8-17 (2014) 
  42. Flück, C E. and Pandey, AV. Steroidogenesis of Testis: New Genes and pathways. Annal d`Endocrinologie. 75: 40-47 (2014). 
  43. Balmer C, Pandey AV, Rüfenacht V, Nuoffer JM, Fang P, Wong LJ, Häberle J. Mutations and polymorphisms in the human argininosuccinate lyase (ASL) gene. Hum Mutat. 35(1):27-35 (2014). 
  44. Camats N, Pandey AV, Fernández-Cancio M, Fernández JM, Ortega AM, Udhane S, Andaluz P, Audí L, Flück CE. STAR splicing mutations cause the severe phenotype of lipoid congenital adrenal hyperplasia: insights from a novel splice mutation and review of reported cases. Clin Endocrinol (Oxf). 80:191-199 (2014). 
  45. Hu L, Pandey AV, Eggimann S, Rüfenacht V, Möslinger D, Nuoffer JM, Häberle J. Understanding the role of argininosuccinate lyase transcript variants in the clinical and biochemical variability of the urea cycle disorder argininosuccinic aciduria. J Biol Chem. 288:34599-611 (2013). IF 4.2
  46. Petkovic V, Miletta MC, Boot AM, Losekoot M, Flück CE, Pandey AV, Eblé A, Wit JM, Mullis PE. Short stature in two siblings heterozygous for a novel bioinactive GH mutant (GH-P59S) suggesting that the mutant also affects secretion of the wild-type GH. Eur J Endocrinol. 168:35-43. (2013). IF 3.9
  47. Pandey, AV and Fluck CE. NADPH P450 oxidoreductase: Structure function and pathology of diseases. Pharmacol & Therapeutics 138: 229-254 (2013). IF 11.0 Citations 
  48. Biason-Lauber A, Miller WL, Pandey AV, Flück CE. Of marsupials and men:”Backdoor” dihydrotestosterone synthesis in male sexual differentiation. Mol Cell Endocrinol. 371: 124-132 (2013). IF 3.8 Citations 
  49. Riddick DS, Ding X, Wolf CR, Porter TD, Pandey AV, Zhang QY, Gu J, Finn RD, Ronseaux S, McLaughlin LA, Henderson CJ, Zou L, Flück CE. NADPH-cytochrome P450 oxidoreductase: roles in physiology, pharmacology, and toxicology. Drug Metab Dispos. 41:12-23 (2013). IF 3.2 Citations 
  50. Camats N, Pandey AV, Fernández-Cancio M, Andaluz P, Janner M, Torán N, Moreno F, Bereket A, Akcay T, García-García E, Muñoz MT, Gracia R, Nistal M, Castaño L, Mullis PE, Carrascosa A, Audí L, Flück CE. Ten novel mutations in the NR5A1 gene cause disordered sex development in 46,XY and ovarian insufficiency in 46,XX individuals. J Clin Endocrinol Metab. 97:E1294-306 (2012) IF 6.2 
  51. Flück CE, Meyer-Böni M, Pandey AV, Kempná P, Miller WL, Schoenle EJ, and Biason-Lauber A. Why Boys will be Boys: Two Pathways of Fetal Testicular Androgen Biosynthesis Are Needed for Male Sexual Differentiation. Am J. Hum Genetics 89:201-218 (2011). IF 10.8
  52. Flück CE, Mallet D, Hofer G, Samara-Boustani D, Leger J, Polak M, Morel Y and Pandey AV. Deletion of P399_E401 in NADPH cytochrome P450 oxidoreductase results in partial mixed oxidase deficiency. Biochem. Biophys. Res. Commun 412: 572-577 (2011). IF 2.5
  53. Flück CE, Pandey AV, Dick B, Camats N, Fernandez-Cancio M, Celmente M, Gussinye M, Carrascosa A, Mullis PE and Audi L. Characterization of novel StAR (Steroidogenic Acute Regulatory Protein) mutations causing non-classic lipoid adrenal hyperplasia. PLoS One 6(5):e20178 (2011). IF 3.2 Citations 
  54. Hirsch A, Meimaridou E, Fernandez-Cancio M, Pandey AV, Clemente, M, Audi L, Clark AJ and Flück CE.  Loss of C Terminus of Melanocortin Receptor 2 (MC2R) Results in Impaired Cell Surface Expression and ACTH Insensitivity. J. Clin. Endocrinol. Metab. 96: 65-72 (2011). IF 6.2 
  55. Petkovik V, Eble A, Pandey AV, Betta M, Mella P, Flück CE, Buzi F and Mullis PE. A novel GH-1 gene mutation (GH-P59L) causes partial GH deficiency type II combined with bioinactive GH syndrome. Growth Horm IGF Res 21: 160-166 (2011). IF 1.5
  56. Flück CE, Mullis PE and Pandey AV. Reduction in hepatic drug metabolizing CYP3A4 activities caused by P450 oxidoreductase mutations identified in patients with disordered steroid metabolism. Biochem. Biophys. Res. Commun 401: 149-153 (2010).
  57. Pandey AV, Flück CE, Mullis PE and. Altered heme catabolism by heme oxygenase-1 caused by mutations in human NADPH cytochrome P450 reductase. Biochem. Biophys. Res. Commun 400: 374-378 (2010).
  58. Nicolo C, Flück CE, Mullis PE and Pandey AV. Restoration of mutant cytochrome P450 reductase activity by external flavin. Mol Cell Endocrinol. 321: 245-252 (2010).
  59. Petkovic V, Godi M, Pandey AV, Lochmatter D, Buchanan CR, Dattani MT, Eble A, Flück CE, Mullis PE. Growth Hormone (DH) Deficiency Type II: A Novel GH-1 Gene Mutation (GH-R178H) Affecting Secretion and Action. J. Clin Encocrinol. Metab. 95: 731-739 (2010).
  60. Flück CE, Mullis PE and Pandey AV. Modeling of human P450 oxidoreductase structure by In-silico mutagenesis and molecular dynamics simulations. Mol Cell Endocrinol 313: 17-22 (2009).
  61. Pepe CM., Saraco NI., Baquedano MS, Guercio G, Vaiani E, Marino R, Pandey AV, Flück CE, Rivarola MA. & Belgorosky A. The cytochrome P450 aromatase lacking exon 5 is associated with a phenotype of nonclassic aromatase deficiency and is also present in normal human steroidogenic tissues. Clin. Endocrinol. 67: 698-705 (2007).
  62. Pandey AV. Biochemical analysis of mutations in P450 oxidoreductase.  Biochem Soc Trans  34: 1186-1191 (2006).
  63. Janner M., Pandey AV, Mullis PE. and Flück CE. Clinical and biochemical description of a novel CYP21A2 gene mutation 962_963InsA using a new 3D model for the P450c21 protein. Eur. J. Endocrinol. 155: 143-151 (2006) (joint First author)
  64. Pandey AV and Miller WL. Regulation of 17,20 lyase activity by cytochrome b5 and by serine phosphorylation of P450c17. J. Biol. Chem. 280: 13265-13271 (2005). Cover Page 
  65. Huang N, Pandey AV, Agrawal V, Reardon W, Lapunzina PD, Mowatt D, Jabs EW, vanVliet G; Sack, J, Flück CE and Miller WL. Diversity and function of mutations in P450 oxidoreductase in patients with Antley-Bixler syndrome and disordered steroidogenesis. Am. J. Hum. Genet. 76: 729-749 (2005) 
  66. Miller WL, Huang N, Flück CE and Pandey AV. P450 oxidoreductase deficiency. Lancet 364: 1663 (2004). 
  67. Pandey AV, Flück CE, Huang N, Tajima T, Fuijeda K and Miller WL. P450 oxidoreductase deficiency: a new disorder of steroidogenesis affecting all microsomal P450 enzymes. Endocrine Res 30: 881-888 (2004). 
  68. Flück CE, Tajima T, Pandey AV, Arlt W, Okuhara K, Verge CF, Jabs EW, Mendonca BB, Fujieda K and Miller WL. Mutant P450 oxidoreductase causes disordered steroidogenesis with and without Antley-Bixler syndrome. Nature Genetics 36: 228-30 (2004). 
  69. Pandey AV; Babbarwal VK; Okoyeh JN; Joshi RM; Puri SK; Singh RL and Chauhan VS. Hemozoin formation in malaria: a two-step process involving histidine-rich proteins and lipids. Biochem Biophys Res Commun. 308:736-743 (2003). 
  70. Pandey AV, Mellon SH and Miller WL. Protein phosphatase 2A and phosphoprotein SET regulate androgen production by P450c17. J Biol Chem. 278:2837-2844 (2003). 
  71. Pandey AV; Bisht H; Babbarwal VK; Srivastava J; Pandey KC and Chauhan VS. Mechanism of malarial haem detoxification inhibition by chloroquine. Biochem J. 355:333-338 (2001). 
  72. Pandey, AV; Tekwani, BL; Singh, RL and Chauhan VS. Artemisinin, an endoperoxide antimalarial, disrupts the hemoglobin catabolism and heme detoxification systems in malarial parasite. J Biol Chem. 274:19383-19388 (1999). 
  73. Pandey AV; Singh N; Tekwani BL; Puri SK and Chauhan VS. Assay of beta-hematin formation by malaria parasite. J Pharm Biomed Anal. 20:203-207 (1999). 
  74. Pandey AV; Joshi SK; Tekwani BL and Chauhan VS. A colorimetric assay for heme in biological samples using 96-well plates. Anal Biochem. 268:159-161 (1999).
  75. Pandey, AV and Chauhan, VS. Heme polymerisation by malarial parasite: A potential target for antimalarial drug development. Current Sci 75:911-918 (1998). 
  76. Pandey AV and Tekwani BL. Depolymerization of malarial hemozoin: a novel reaction initiated by blood schizontocidal antimalarials. FEBS Lett. 1997 402:236-240 (1997). Cover Page 
  77. Pandey AV; Joshi R; Tekwani BL; Singh RL and Chauhan VS. Synthetic peptides corresponding to a repetitive sequence of malarial histidine rich protein bind haem and inhibit haemozoin formation in vitro. Mol Biochem Parasitol. 90:281-287 (1997). 
  78. Pandey AV and Tekwani BL. Formation of haemozoin/beta-haematin under physiological conditions is not spontaneous. FEBS Lett. 393:189-193 (1996). 
  79. Pandey, AV; Srivastava, P; Tekwani, BL and Pandey, VC Effect of Plasmodium yoelii infection on constitutive and phenobarbitone inducible mixed function oxidase system of mice. J. Parasit. Dis. 20:141-144 (1996). 
  80. Pandey AV and Tekwani BL. Identification and quantification of haemozoin: Some additional facts. Trends Parasitol. 12:370 (1996). 
  81. Pandey, AV, Tekwani, BL and Pandey, VC Characterisation of hemozoin from liver and spleen of mice infected with Plasmodium yoelii, a rodent malaria parasite. Biomed. Res. 16:115-120 (1995). 
  82. Flück, CE, Rojas Velazquez, MN and Pandey, AV. P450 oxidoreductase deficiency. In Genetic Steroid Disorders 2nd Edition. Ed: Maria I New. 125-143 Elsevier (2023).DOI: https://doi.org/ 10.1016/B978-0-12-821424-4.00012-5
  83. Sarah C Sim, Walter L Miller, Xiao-Bo Zhong, Wiebke Arlt, Tsutomu Ogata, Xinxin Ding, C Roland Wolf, Christa E Fluck, Amit V Pandey, Colin J Henderson, Todd D Porter, Ann K Daly, Daniel W Nebert, and Magnus Ingelman-Sundberg. Nomenclature for Alleles of the Cytochrome P450 Oxidoreductase (POR) Gene. Pharmacogenetics and Genomics 19: 565-566 (2009)
  84. Hooley E, Papagrigoriou E, Navdaev A, Pandey AV, Clemetson JM, Clemetson KJ, Emsley J. The crystal structure of the platelet activator aggretin reveals a novel (alphabeta)2 dimeric structure. Biochemistry. 47:7831-7837 (2008).
  85. Fluck CE, Pandey AV, Huang N, Agrawal, V & Miller WL. P450 oxidoreductase deficiency – a new form of congenital adrenal hyperplasia.  Endocr Dev 13: 67-81 (2008).
  86. Pandey AV, Kempna P, Hofer G, Mullis PE & Flück CE. Modulation of human CYP19A1 activity by mutant NADPH P450 oxidoreductase.  Mol Endocrinol 21: 2579-2595 (2007).
  87. Flück CE, Nicolo C & Pandey AV. Clinical structural and functional implications of mutations and polymorphisms in human NADPH P450 oxidoreductase. Fund. Clin. Pharmacol. 21: 399-410 (2007).
  88. Konrad M, Schaller A, Seelow D, Pandey AV, Waldegger S, Lesslauer A, Vitzthum H, Suzuki Y, Luk JM, Becker C, Schlingmann KP, Schmid M, Rodriguez-Soriano J, Ariceta G, Cano F, Enriquez R, Juppner H, Bakkaloglu SA, Hediger MA, Gallati S, Neuhauss SC, Nurnberg P, Weber S. Mutations in the tight-junction gene claudin 19 (CLDN19) are associated with renal magnesium wasting, renal failure, and severe ocular involvement. Am. J. Hum. Genet. 79: 949-957 (2006). 
  89. Miller WL, Huang N, Pandey AV, Flück CE, Agrawal V. P450 oxidoreductase deficiency: A new disorder of steroidogenesis. Ann NYAS 1061:100-108 (2005).
  90. Biason-Lauber, A, Pandey AV, Miller WL, Flück, CE. Steroidogenesis across species: aldo keto reductases in marsupials, fish and humans. . In Genetic Steroid Disorders 2nd Edition. Ed: Maria I New. Elsevier (2023). https://doi.org/10.1016/B978-0-12-821424-4.00002-2
  91. Flück CE and Pandey AV. Human P450 oxidoreductase deficiency. In Encyclopedia of Endocrine Diseases 2nd Edition. (2019). Elsevier. Editors: Ilpo Huhtaniemi and Luciano Martini. ISBN: 978-0-12-812200-6
  92. Pandey AV, Henderson CJ, Ishi Y, Kranendonk M, Backes WL, Zanger UM. Book: Role of protein protein interaction in metabolism: Genetics, structure, function. (2018) DOI:10.3389/978-2-88945-385, Publisher: Frontiers Media SA, Lausanne.ISBN: 978-2-88945-385-6
  93. Flück CE and Pandey AV. Testicular steroidogenesis and testosterone. In Endocrinology: Endocrinology of the testis and male reproduction. 2017 Springer-Nature doi:10.1007/978-3-319-29456-8_10-1 Review Article
  94. Flück,CE and Pandey, AV. P450 oxidoreductase deficiency (PORD). In Genetic Steroid Disorders. Editor: Maria I New. pp 125-143 Elsevier (2013).
  95. Flück,CE; Miller, WL; Pandey, AV; Biason-Lauber, A. Marsupial pathways in humans. In Genetic Steroid Disorders. Editor: Maria I New. pp 215-224 Elsevier (2013).
  96. Pandey, AV. Bioinformatics tools and databases for study of human growth hormone. Endocrine Dev 23:71-85 (2012).
  97. Flück CE and Pandey AV. Clinical and biochemical consequences of P450 oxidoreductase deficiency. Endo. Dev. 20: 63-79 (2011).
  98. Pandey AV and Mullis PE. Molecular genetic and bioinformatic Methods for diagnosis of endocrine disorders. In: Diagnostics of endocrine function in children and adolescents. (Ranke MB and Mullis PE. Editors), Karger, Basel ISBN: 978-3-8055-9414-1 pp 32-52 (2011).
  99. Pandey, AV and Chauhan VS. New targets for malaria drug development. In Multi-Drug Resistance in Emerging and Re-Emerging Diseases. (Mahajan, RC, Therwath, A. Edts), CRC Press LLC, Boca Rattan, FL 147-156, (2002). 
  100. Pandey, AV and Chauhan, VS New Drug targets in Malaria. In Emerging and re-emerging infections. Narosa Publications pp 122-127 (2000)

 

 

© Copyright. All rights reserved.